U.S. Academic Medical Center Venture Capital Investments
ozempic adn Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated significant weight loss,the cardiovascular safety signal is prompting a reassessment of it’s use in this specific patient population.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. importantly, the weight loss achieved with semaglutide – an average of approximately 15% of initial body weight – did *not* appear to offset this cardiovascular risk. The findings were presented at the European Congress on Obesity and concurrently published online.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Heart Attack, Stroke, Cardiovascular Death) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.0 | 2.5 | 1.20 |
| Non-fatal Stroke | 1.7 | 1.3 | 1.31 |
| Non-Fatal Heart Attack | 2.5 | 1.9 | 1.32 |
Who is Affected? Understanding Patient Risk Profiles
These findings primarily impact individuals with obesity *and* pre-existing cardiovascular disease, such as a history of heart attack, stroke, or peripheral artery disease.The trial did *not* include patients with type 2 diabetes, raising questions about whether the cardiovascular risk profile differs in that population. Currently, semaglutide is widely used both for weight management and for treating type 2 diabetes, making this distinction crucial. Individuals without established cardiovascular disease may not face the same elevated risk, but further research is needed to confirm this.
It’s vital to note that the study population was specifically chosen for its high cardiovascular risk. Extrapolating these results to the broader population of individuals with obesity requires caution.
Why Does this matter? The Shifting Landscape of GLP-1 Receptor Agonists
Semaglutide, a GLP-1 receptor agonist, has been widely touted for its weight loss benefits and, in some earlier studies, suggested potential cardiovascular protection, particularly in individuals with type 2 diabetes. The SELECT trial challenges this narrative, highlighting the importance of considering the overall health profile of patients before prescribing these medications. This finding underscores that weight loss alone does not guarantee cardiovascular benefit and that the underlying mechanisms of GLP-1 receptor agonists are complex and not fully understood.